These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 898287)

  • 1. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
    Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
    Tumori; 1977; 63(2):169-73. PubMed ID: 898287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
    Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
    McMahon LJ; Jones SE; Durie BG; Salmon SE
    Cancer Lett; 1975 Nov; 1(2):97-102. PubMed ID: 65213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.
    Anderson G; Bowyer F; Williams L
    Thorax; 1981 Jun; 36(6):462-4. PubMed ID: 7314017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
    Schmieder HA; Jungi WF; Mayr AC; Senn HJ
    Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
    Morasca L; Marsoni S; Pisoni MB; Piazza E; Vago G; Casali W; Cogo R; Bianchi C; Scapaticci R
    Cancer Chemother Pharmacol; 1982; 7(2-3):209-10. PubMed ID: 7083461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine.
    Alberto P; Brunner KW; Martz G; Obrecht J; Sonntag RW
    Cancer; 1976 Dec; 38(6):2208-16. PubMed ID: 187313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
    Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
    Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy in bronchogenic carcinoma.
    Ojala A; Nikkanen VN; Palojoki A; Paloheimo S
    Ann Clin Res; 1977 Feb; 9(1):12-4. PubMed ID: 329741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma.
    Hansen HH; Muggia FM; Andrews R; Selawry OS
    Cancer; 1972 Aug; 30(2):315-24. PubMed ID: 4559404
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral VP-16-213 in advanced bronchogenic carcinoma.
    Cantwell B
    Thorax; 1981 Sep; 36(9):719-20. PubMed ID: 7314052
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside).
    Hansen M; Hirsch F; Dombernowsky P; Hansen HH
    Cancer; 1977 Aug; 40(2):633-7. PubMed ID: 196736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between myelosuppression and chemotherapeutic response in small cell bronchogenic carcinoma.
    Holoye PY
    Exp Hematol; 1985; 13 Suppl 16():72-9. PubMed ID: 2985416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
    Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
    Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of bronchopulmonary small cell carcinoma with a combination of cyclophosphamide and VP-16].
    González Larriba JL; Ordóñez Gallego A; Díaz Pérez MA; García de Paredes ML; Zamora P; Montero García JM
    Med Clin (Barc); 1984 May; 82(19):836-9. PubMed ID: 6330470
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination chemotherapy with cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in advanced bronchogenic carcinoma: experience with 106 patients.
    Samson MK; Baker LH; Fraile RJ; Izbicki RM; Vaitkevicius VK
    Cancer Treat Rep; 1977; 61(1):59-64. PubMed ID: 67895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VP-16 and adriamycin in patients with advanced breast cancer.
    Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
    Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung.
    Weiss AJ; Wilson WL
    Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.